BRAFV600E mutation analysis in papillary thyroid carcinoma: Is it useful for all patients?

World Journal of Surgery

Volumn 38, Issue 3, 2014, Pages 679-687

  Ito, Yasuhiro ^a   Yoshida, Hiroshi ^a   Kihara, Minoru ^a   Kobayashi, Kaoru ^a   Miya, Akihiro ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOMA; EVALUATION STUDY; FEMALE; FOLLOW UP; GENETIC MARKER; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL; THYROID TUMOR; THYROIDECTOMY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84894647237     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2223-2     Document Type: Article

References (49)

1. Ito Y, Tomoda C, Uruno T et al (2006) Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 30:780-786. doi: 10.1007/s00268-005-0270-z
2. Ito Y, Tomoda C, Uruno T et al (2005) Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 29:917-920. doi: 10.1007/s00268-005-7789-x
3. Ito Y, Kudo T, Kobayashi K et al (2012) Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5,768 patients with 10-year follow-up. World J Surg 36:1274-1278. doi: 10.1007/s00268-012-1423-5
4. Marais R, Marshall CJ (1996) Control of the ERK MAP kinase cascade by Ras and Raf. In: Parker PJ, Pawson T (eds) Cell signaling. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 101-125
5. Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40
6. Namba H, Nakashima M, Hayashi T et al (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397
7. Kim TY, Kim WB, Rhee YS et al (2006) The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 65:364-368
8. Ademiran AJ, Zhu Z, Gandhi M et al (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222
9. Fugazzola L, Peuxeddu E, Avenia N et al (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13:455-464
10. Kebebew E, Weng J, Bauer J et al (2007) The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 246:466-471
11. Lupi C, Glannini R, Ugolini C et al (2007) Association of BRAF V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 92:4085-4090
12. Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
13. V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 13:257-269
14. Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
15. Frasca F, Nucera C, Pelligreti G et al (2008) BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 15:191-205
16. Ellisei R, Ugolini C, Viola D et al (2008) BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
17. Kwak JY, Ekim EK, Chung WY et al (2009) Association of BTAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253:854-860
18. O'Neill CJ, Bullock M, Chou A et al (2010) BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148:1139-1145
19. Kim TH, Park YJ, Lim JA et al (2012) The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 118:1764-1773
20. Tufano RP, Telxeira FB, Bishop J et al (2012) BRAF mutation in papillary tyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 91:274-286
21. V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97:4559-4570
22. V600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results form a large cohort study. J Clin Endocrinol Metab 97:4390-4398
23. V600E alleles in papillary thyroid carcinoma predicts a poorer outcome. J Clin Endocrinol Metab 97:2333-2340
24. Ricarte-Filho J, Ganly I, Rivera M et al (2012) Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension. Thyroid 22:575-584
25. V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 36:310-317. doi: 10.1007/s00268-011-1383-1
26. V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery 152:984-990
27. Abrosimov A, Saenko V, Rogounovitch T et al (2007) Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 120:196-200
28. Fugazzola L, Mannavola D, Cirello V et al (2004) BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 61:239-243
29. Sapino MR, Posca D, Raggioli A et al (2007) Detection of RET/PTC, TRK, and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. Clin Endocrinol 66:678-683
30. Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K et al (2007) Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro Endocrinol Lett 28:351-359
31. V600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinoil 63:588-593
32. V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol 63:461-466
33. Stanojevic B, Dzodic R, Saenko V et al (2011) Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia. Endocr J 58:381-393
34. V600E mutation does not mean distant metastasis in thyroid papillary carcnomas. J Clin Endocrinol Metab 97:1745-1749
35. Kurt B, Yalcun S, Alagoz E et al (2012) The relationship of the BRAF(V600E) mutation and the established prognostic factors in papillary thyroid carcinomas. Endocr Pathol 23:135-140
36. V600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval. Clin Endocrinol 77:780-786
37. V600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nesus Larynx 39:198-203
38. Nam JK, Jung CK, Song BJ et al (2012) Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 203:436-441
39. Ito Y, Yoshida H, Maruo R et al (2008) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97
40. Cady B, Rosai R (1988) An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 104:947-953
41. Hay ID, Bergstrahl EJ, Goellner JR et al (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058
42. Sobin LH, Wittekind CH (eds) (2011) UICC: TNM classification of malignant tumors, 7th edn. Wiley, New York
43. Sugitani I, Kasai N, Fujimoto Y et al (2004) A novel classification system for patients with PTC: addition of the new variable of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 135:139-148
44. Ito Y, Ichihara K, Masuoka H et al (2010) Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma. World J Surg 34:2570-2580. doi: 10.1007/s00268-010-0710-2
45. Durante C, Puxeddu E, Feretti E et al (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840-2943
46. 18F] fluoro-2-deoxy-d-glucose uptake ability. Eur J Endocrinol 163:659-663
47. Gao WL, Wie LL, Chao YG et al (2012) Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin Lab 58:919-926
48. V600E is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 97:517-524
49. Brose MS, Nutting C, Jarzab B, et al (2013) Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer. The phase III DECISION trial. The 49th annual meeting of the American Society of Clinical Oncology (ASCO) Plenary session Abstract #4